- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04741594
Osseodensification and Implant Survival and Success
June 8, 2026 updated by: University of Oklahoma
Alveolar Ridge Expansion by Osseodensification and Its Impact on Implant Survival and Success: A Case Series
Approximately 40 implants from patients seeking treatment at the University of Oklahoma, College of Dentistry will be recruited for this study.
Osteotomies will be prepared using the osseodensification technique and implants will be placed immediately after.
The implants will be from a single manufacturer (Roxolid® SLA® Bone Level Tapered; Straumann®, Institut Straumann AG, Basel, Switzerland).
Volumetric analysis of alveolar ridge will be studied using intra-surgical direct measurements and CBCT imaging.
A custom stent will be fabricated to standardize the clinical and radiographic measurements at 2mm, 3mm, and 4mm apical to the alveolar crest.
Changes in peri-implant bone density will be analyzed on standardized periapical and bitewing radiographs, using the ImageJ software (National Institute of Health, Bethesda, Maryland, USA).
Implant stability quotient (ISQ) values will be recorded with a resonance frequency analysis system (Osstell®, Gothenburg, Sweden).
Calibrated examiners will assess implant survival and biological or restorative complications and failures.
Sites will be evaluated throughout osseointegration and one year after final restoration is delivered.
Study Overview
Detailed Description
The purpose of this study was to determine the efficacy for alveolar ridge expansion and change in peri-implant density when prepared by the osseodensification technique.
The retention of this volume throughout osseointegration and loading were evaluated.
The changes in bone volume were recorded by CBCT and intra-surgical direct measurements.
A standardizing stent was used for the CBCT and direct measurements with a caliper.
CBCT was taken before and after osseodensification, and 1 year after delivery of final restoration.
Standardized periapical and bitewing radiographs were also taken to evaluate marginal bone loss and peri-implant bone density.
Calibrated examiners evaluated implant survival and failure rate, ISQ value, peri-implant pocket depth, plaque index, bleeding index, gingival index, biological and restorative complications.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73117
- College of Dentistry, OUHSC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
4. Inclusion / Exclusion Criteria
The inclusion criteria include:
- Adult patients ≥18 years old
- Able to understand and sign a written informed consent form and willing to fulfil all study requirements
- Healed edentulous ridge that is planned for an implant restoration.
- Experimental site has not been previously augmented with xenograft
- Experimental site has at least 2 mm of cancellous bone
The exclusion criteria include:
- Uncontrolled systemic disease
- Currently smoking >10 cigarettes/day
- History of head/neck radiotherapy within the past five years
- Current use of oral bisphosphonates or history of IV bisphosphonate use
- Pregnant, expecting to become pregnant, or lactating women
- Presence of active periodontal disease
- Poor oral hygiene
- Previous history of implant failure at the site
The early termination criteria include:
- The researcher believes that it is not in the patient's best interest to stay in the study
- Based on the exclusion criteria, the patient becomes ineligible to participate
- Patient's medical condition requires interventions which preclude involvement in the study (radiation therapy, chemotherapy, etc)
- Patient does not follow study related instructions
- The study is suspended or canceled
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Versah group
The use of a Versah bur, which is an implant drill bit, is different than a standard implant drill bit, in that its use creates a more dense bone, by using a technique called osseodensification.
The drill bit and technique are specific to this drill bit and protocol, resulting in denser bone for subsequent implant placement.
|
Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement.
Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA).
This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies.
Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge.
Human clinical studies have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods.
No standardization method or long-term evaluation of peri-implant health was reported.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone Width (mm)
Time Frame: Measurements were taken at baseline and 3 months after implant placement.
|
Bone width at 2, 3, 4 mm apical to edentulous alveolar ridge.
Not all measurements were able to be performed on each site due to anatomic limitations per site.
Results were reported at 2 mm below the alveolar crest and 4 mm below the alveolar crest, when applicable.
Measurements were performed by caliper measurements during the procedure and by CBCT followup approximately 3 months after implant placement
|
Measurements were taken at baseline and 3 months after implant placement.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Implants That Survived
Time Frame: The extent of the study was approximately 3 months after implant placement. There is some small variability in the time frame for each implant placed based on scheduling of each patient.
|
This outcome measure emphasizes the number of implants in this study that have survived for analysis.
|
The extent of the study was approximately 3 months after implant placement. There is some small variability in the time frame for each implant placed based on scheduling of each patient.
|
|
Change in Implant Stability
Time Frame: From Initial Placement to 3 month follow-up - approximately 3 months
|
Implant stability quotient (ISQ) values were performed at the time of implant placement and at the 3-month follow-up appointment, if possible.
Osstell uses Resonance Frequency Analysis to determine implant stability.
The result is presented as an ISQ (Implant Stability Quotient) value of 1-100.
The higher the ISQ, the more stable the implant.
Measure at implant placement for a baseline reading and again before final restoration.
|
From Initial Placement to 3 month follow-up - approximately 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robin Henderson, University of Oklahoma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2021
Primary Completion (Actual)
February 21, 2022
Study Completion (Actual)
September 13, 2023
Study Registration Dates
First Submitted
January 15, 2021
First Submitted That Met QC Criteria
February 2, 2021
First Posted (Actual)
February 5, 2021
Study Record Updates
Last Update Posted (Actual)
June 25, 2026
Last Update Submitted That Met QC Criteria
June 8, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12966
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.